• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Special Reports
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Resources
    • About MassDevice
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
    • In-Depth Coverage
    • Latest News
  • Attend DeviceTalks
    • Events
      • DeviceTalks Minnesota – May 4
      • DeviceTalks Boston – May 27–28
      • DeviceTalks West
      • DeviceTalks Tuesdays
    • DeviceTalks Podcast Network
      • DeviceTalks Weekly
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Advertise
  • Subscribe
Home » BCI maker Zander Labs looks to bring neurotech to US

BCI maker Zander Labs looks to bring neurotech to US

March 12, 2026 By Sean Whooley

Zander Labs LogoZander Labs announced today that it plans to bring its brain-computer interface (BCI) technology to the U.S.

The Dutch-German neuroadaptive AI company develops passive BCI (pBCI) and human-computer interactive technology. It hopes to make its offerings available to a wider range of organizations with its entry to the U.S. market.

In 2026, Zander Labs plans to actively seek partners in the U.S., with a particular focus on the West Coast. It could target sectors like defense, mobility, robotics, healthcare and other human-centered AI applications. The company wants partners interested in integrating its neuroadaptive AI platform to create smarter systems for their own solutions.

Zander Labs’ technologies respond to human mental states in real time through pBCI technology. It continuously and subconsciously measures brain activity without requiring active input from the user. The technology captures and processes signals, combining them with contextual data and AI algorithms. It enables AI-powered systems to respond to a safer, more human-centered, more intuitive way.

The company featured on our 2024 list of BCI companies to know. Read more here.

The company originated from a collaboration between Dutch and German researchers. A few years ago, it earned a $33 million German contract to develop BCI prototypes. Today, it combines fundamental neuroscience research with applied AI and hardware development.

“Our technology is not an end product but a building block,” said Jonathan Zwaan, CEO of Zander Labs. “We want to work with partners who share our belief that the future of AI and technology is neuroadaptive. The U.S. market offers a tremendous opportunity to integrate our neuroadaptive AI technology into new, innovative solutions. The recent developments and milestones we achieved show that we are technologically ready for the next step and are able to work with global partners on new use cases that will have global impact.”

Filed Under: Artificial Intelligence (AI), Brain-Computer Interface (BCI), Business/Financial News, Emerging Markets, Health Technology, Implants, Machine Learning (ML), Neurological, Research & Development, Software / IT Tagged With: Zander Laboratories

More recent news

  • Boston Scientific continues to make progress on cyberattack recovery
  • Edwards Lifesciences, Medtronic score CMS win for TAVR
  • Stryker still working through cyberattack after-effects, stock down more than 10% this week
  • Siemens Healthineers completes $44M R&D, manufacturing site expansion
  • Next-gen Apple Watch Ultra 4 includes new health features

About Sean Whooley

Sean Whooley is a senior editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

Cart

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >
MDO ad
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2026 · Arrowfly LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy